Biora Therapeutics Past Earnings Performance

Past criteria checks 0/6

Biora Therapeutics has been growing earnings at an average annual rate of 21.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 87.6% per year.

Key information

21.3%

Earnings growth rate

85.6%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-87.6%
Return on equityn/a
Net Margin-3,988.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Biora Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BST:4ZU0 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241-363526
30 Jun 241-873731
31 Mar 241-1113830
31 Dec 230-1243730
30 Sep 230-1223829
30 Jun 230-643325
31 Mar 230-523325
31 Dec 220-493824
30 Sep 221-1184227
30 Jun 221-1405233
31 Mar 221-1766741
31 Dec 211-1797346
30 Sep 211-1467649
30 Jun 211-1427549
31 Mar 21-16-1064848
31 Dec 200-1056048
30 Sep 2021-1427551
30 Jun 2039-2078955
31 Mar 20113-21812259
31 Dec 19144-22912063
30 Sep 19120-21111663
31 Dec 18128-12910149

Quality Earnings: 4ZU0 is currently unprofitable.

Growing Profit Margin: 4ZU0 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4ZU0 is unprofitable, but has reduced losses over the past 5 years at a rate of 21.3% per year.

Accelerating Growth: Unable to compare 4ZU0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4ZU0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 4ZU0's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies